Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 14/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446955 | 0.85 | PDE3B (0.43) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL17446924 | 0.83 | PDE3B (0.48) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL17446918 | 0.83 | PDE3B (0.42) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL17446937 | 0.83 | PDE3B (0.42) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL17446920 | 0.80 | PDE3B (0.40) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL16157002 | 0.79 | PDE3B (0.61) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL7296342 | 0.79 | PDE3B (0.61) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL17446917 | 0.79 | PDE3B (0.39) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL17446932 | 0.79 | PDE3B (0.39) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL17446942 | 0.77 | PDE3B (0.44) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | GPR119 2110/4885PDE3B 2667/4885PDE3A 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.